160 results
Page 2 of 8
8-K
EX-99.1
3brzod3o wx
3 Nov 23
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
8:10am
8-K
EX-99.1
ibw5y
18 Oct 23
Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid
8:04am
8-K
EX-99.1
1vz3wsu
2 Oct 23
Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman
12:15pm
8-K
EX-99.1
y9xu1d ekpcyp00k9eg
4 Aug 23
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
9:10am
8-K
EX-99.1
ogdin4 r9i5isgsort81
5 May 23
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
8:16am
8-K
EX-99.1
x2rao
1 May 23
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
4:17pm
8-K
2dm d94ujejgosgdg
1 May 23
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
4:17pm
8-K
EX-99.1
je4tzrclyt
27 Apr 23
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
4:43pm
8-K
EX-99.1
gbb940ybr
8 Nov 22
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
8:41am